What happened

AEON Biopharma, Inc. (NYSE American: AEON) said FDA Type 2b minutes support a potentially more efficient ABP-450 biosimilar development path. The FDA agreed in principle with AEON's proposed initial dose-finding stage in healthy volunteers for a comparative pharmacodynamic study using Compound Muscle Action Potential measurement.

AEON said it plans to submit an IND for that CMAP study in the fourth quarter of 2026 and to start the study in the first quarter of 2027. The company also said the FDA indicated earlier ABP-450 head-to-head studies versus BOTOX may be submitted as supportive evidence, if AEON completes scientific bridging work. AEON said it does not intend to start a standalone comparative efficacy study now.

Separately, AEON said the minutes do not preclude advancement toward a BLA under Section 351(k). On that basis, the Two-Year Milestone Warrants now expire on November 16, 2026, unless exercised earlier.

Explain the financial terms

A fiscal quarter is a three-month period in the company's reporting year.

Why it matters

For OptimistFi's case, the filing nudges ABP-450 closer to a testable biosimilar path without giving AEON a biosimilarity finding. That matters because the U.S. therapeutic neurotoxin market exceeds $3.0 billion annually, and AEON says it wants to rely on analytical, pharmacodynamic and comparative human evidence to support a streamlined program.

The support is conditional, though. The FDA tied the prior studies to scientific bridging to U.S.-licensed BOTOX and to ABP-450 as currently manufactured, and said any added clinical evidence should be sensitive enough to detect a meaningful difference. The company still has to show that its evidence package is complete enough to avoid a standalone comparative efficacy study.

What's next

AEON plans to file the IND in the fourth quarter of 2026, then begin the CMAP study in the first quarter of 2027. It also plans to return to the FDA in 2027 with its integrated evidence package.

If the company shows progress on analytical work, bridging and the CMAP study, the case for a leaner path strengthens. If the FDA asks for additional analytical, pharmacodynamic or clinical studies, the story weakens.

Explain the financial terms

A fiscal quarter is a three-month period in the company's reporting year.

Sources checked automatically Sep 30, 2026 · Human review: none
Thesis impactAEON: no published thesis yet.